Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omburtamab I-124 - Y-mAbs Therapeutics

Next Previous
Drug Profile

Omburtamab I-124 - Y-mAbs Therapeutics

Alternative Names: 124I-8H9; 124I-8H9 (B7-H3)

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diffuse intrinsic pontine glioma

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(In adolescents, In children, Second-line therapy or greater, In adults) in USA (Intratumoural, Infusion)
  • 27 May 2022 Y-mAbs Therapeutics in collaboration with Memorial Sloan Kettering Cancer Center completes a phase I trial in Diffuse intrinsic pontine glioma (In children, In adolescents, In adults, Second-line therapy or greater) in USA (NCT01502917)
  • 24 Feb 2022 Y-mAbs Therapeutics in collaboration with Memorial Sloan Kettering Cancer Center terminates a Phase I trial in Diffuse intrinsic pontine glioma (In children, In adolescents, In adults, Second-line therapy or greater) in USA, as the stopping rule was met per protocol (NCT01502917)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top